These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 17311556)

  • 1. Emerging roles of cysteine cathepsins in disease and their potential as drug targets.
    Vasiljeva O; Reinheckel T; Peters C; Turk D; Turk V; Turk B
    Curr Pharm Des; 2007; 13(4):387-403. PubMed ID: 17311556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
    Yasuda Y; Kaleta J; Brömme D
    Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents.
    Deaton DN; Kumar S
    Prog Med Chem; 2004; 42():245-375. PubMed ID: 15003723
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent developments in cathepsin K inhibitor design.
    Grabowskal U; Chambers TJ; Shiroo M
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):619-30. PubMed ID: 16159024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design.
    Brömme D; Kaleta J
    Curr Pharm Des; 2002; 8(18):1639-58. PubMed ID: 12132996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice.
    Svelander L; Erlandsson-Harris H; Astner L; Grabowska U; Klareskog L; Lindstrom E; Hewitt E
    Eur J Pharmacol; 2009 Jun; 613(1-3):155-62. PubMed ID: 19358841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.
    Falgueyret JP; Desmarais S; Oballa R; Black WC; Cromlish W; Khougaz K; Lamontagne S; Massé F; Riendeau D; Toulmond S; Percival MD
    J Med Chem; 2005 Dec; 48(24):7535-43. PubMed ID: 16302795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools.
    Desmarais S; Massé F; Percival MD
    Biol Chem; 2009 Sep; 390(9):941-8. PubMed ID: 19453281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathepsin K: a therapeutic target for bone diseases.
    Zhao Q; Jia Y; Xiao Y
    Biochem Biophys Res Commun; 2009 Mar; 380(4):721-3. PubMed ID: 19338743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical properties and regulation of cathepsin K activity.
    Lecaille F; Brömme D; Lalmanach G
    Biochimie; 2008 Feb; 90(2):208-26. PubMed ID: 17935853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
    Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
    Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteine cathepsins and extracellular matrix degradation.
    Fonović M; Turk B
    Biochim Biophys Acta; 2014 Aug; 1840(8):2560-70. PubMed ID: 24680817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
    Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
    Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
    Wang D; Li W; Pechar M; Kopecková P; Brömme D; Kopecek J
    Int J Pharm; 2004 Jun; 277(1-2):73-9. PubMed ID: 15158970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin K inhibitors as treatment of bone metastasis.
    Le Gall C; Bonnelye E; Clézardin P
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):218-22. PubMed ID: 18685424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
    Black WC; Percival MD
    Chembiochem; 2006 Oct; 7(10):1525-35. PubMed ID: 16921579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based development of specific inhibitors for individual cathepsins and their medical applications.
    Katunuma N
    Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(2):29-39. PubMed ID: 21321479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K.
    Setti EL; Venkatraman S; Palmer JT; Xie X; Cheung H; Yu W; Wesolowski G; Robichaud J
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4296-9. PubMed ID: 16750630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of cathepsin K inhibitors for osteoporosis.
    Deaton DN; Tavares FX
    Curr Top Med Chem; 2005; 5(16):1639-75. PubMed ID: 16375747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.